Titan Pharmaceuticals, Inc. This groundbreaking technology has the potential to revolutionize the treatment of various chronic diseases by maintaining consistent, around-the-clock blood levels of medication. The ProNeura technology involves the use of a small, flexible implant made from a mixture of EVA and a drug substance.

This implant is placed subcutaneously, typically in the inner part of the upper arm, through a simple office procedure. It can be easily removed at the end of the treatment period. One of Titan Pharmaceuticals' flagship products based on ProNeura is the Probuphine® (buprenorphine) implant, which has been approved in the United States, Canada, and the European Union for the maintenance treatment of opioid use disorder.

While Titan has decided to discontinue selling Probuphine, it remains committed to its ProNeura-based product development programs. They are currently focusing on developing an implant for the treatment of moderate-to-severe chronic pruritus and another implant for the prevention of relapse in patients with opioid use disorder following detoxification from opioids. With a strong intellectual property portfolio and a highly experienced leadership team, Titan Pharmaceuticals is at the forefront of innovation in the field of long-term drug delivery